Colorectal cancer (CRC) is one of the two most commonly diagnosed cancers, with approximately 1.2 million new cases each year and more than 600,000 annual deaths estimated to occur worldwide. 1 In addition, roughly one-fifth of patients present with incurable disseminated disease. 2 In the last decade, the development of new chemotherapeutic biological agents has significantly improved overall survival (OS) of these patients. however, the advantage of a palliative resection of the primary tumour has never been assessed properly. 19 Moreover, most studies do not even report whether a resection of the primary tumour has been performed.
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A palliative resection of the primary tumour is frequently performed 13 and there is a clear indication for surgery when patients present with symptoms of the primary tumour. However, if patients present with absent or mild symptoms, the indication for resection is less obvious. Since patients with incurable metastatic CRC (mCRC) only have a relatively limited life expectancy, and resection of the primary tumour is accompanied by both morbidity and mortality, [14] [15] [16] it is under debate whether resection of the primary tumour has an effect on survival or quality of life. 17, 18 Many studies concerning the management of incurable stage IV CRC have been performed; however, the advantage of a palliative resection of the primary tumour has never been assessed properly. 19 Moreover, most studies do not even report whether a resection of the primary tumour has been performed. 20 In this article we aim to evaluate the role of surgery of the primary tumour in stage IV CRC with unresectable metastases.
Treatment of Metastatic Colorectal Cancer
At diagnosis of CRC, approximately 20 % of patients present with synchronous mCRC, and the liver is the predilection site in half of these patients. 21, 22 The lungs represent the second most common site of metastases from CRC and, according to non-population-based studies, lung metastases are present in 10-15 % of patients with CRC. 23, 24 When metastases are limited, a possible curative treatment can be obtained by surgical resection; however, only 15-20 % of patients are resectable. 25 Median five-year survival for patients undergoing an R0 resection of the metastases is approximately 30 % (range 15-67 %). 26 Despite complete resection and neoadjuvant or adjuvant chemotherapy regimens, recurrences occur in 75 % of the patients. 27 Extrahepatic disease in combination with liver metastases was generally considered a contraindication for surgery. 28 Other studies have shown no association between the incidence of complications and the extent of metastatic disease. 39, 40 Due to recent advances in systemic chemotherapy, the risks and benefits of immediate or deferred surgical strategies are under debate.
Some clinicians in favour of the surgical approach argue that if the asymptomatic primary cancer is not resected, patients will develop disabling symptoms, such as weight loss and nutritional depletion (secondary to 'near' obstruction), and anaemia, due to bleeding of the primary tumour. Arguments supporting surgery include a lower reported operative mortality for elective surgery in patients with stage IV disease (3-6 %), compared with the more threatening operative mortality rates for non-elective resections in patients with advanced and symptomatic disease (20-40 %). 34, 41, 42 Another argument supporting this concept is that pre-operative staging is sometimes unclear and that surgery is considered the last and most effective diagnostic tool for the correct staging of abdominal tumours before treatment. 19 In addition, patients are provided with psychological comfort who feel that the 'cancer' has been removed.
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Chemotherapy First in Patients with Unresectable Synchronous Metastatic Colorectal Cancer
The advocates of a chemotherapy-first approach prefer to avoid complications, at least in asymptomatic patients. The argument of those who prefer 'elective' surgery, due to higher mortality if emergency surgery is required, was addressed in several studies, where the risk of death was found to be extremely low. 39, [43] [44] [45] In fact,
Poultsides and Paty compared their study population with studies with elective colon resection in the metastatic setting and found that it appears that this deferred approach is associated with at least comparable peri-operative mortality. 46 Another argument for chemotherapy first is that chemotherapy will not only treat the metastases but also the primary tumour; many patients will have improvements of their symptoms, therefore avoiding a possible resection. 37, 47 Chau et al. demonstrated that, overall, 86 % of patients had an improvement in symptoms. Of the patients with symptoms, 71 % had diminished pelvic pain/tenesmus, 90 % had improvement in diarrhoea/constipation, 100 % had reduced rectal bleeding and 93 % had weight stabilisation or weight gain.
Advocates of the deferred surgical approach argue that surgery at diagnosis can delay or even preclude systemic chemotherapy, and that most patients will never develop symptoms and these patients Table 1 ). 34, 50 After and investigated the prognostic and predictive value of resection of the primary tumour in stage IV mCRC patients. 54 They demonstrated that resection of the primary tumour was a significant prognostic factor for survival in these patients. They also performed a review of the literature and identified 22 non-randomised studies, most of which showed improved survival for mCRC patients who underwent resection of the primary tumour. These results were confirmed in a systemic review by Anwar et al. 48 An overview of these studies is presented in Table 2 .
However, in all the studies presented a selection bias cannot be excluded. Most studies were not randomised, were performed in single centres and were retrospective in nature. Patients with a good performance status were more likely to undergo surgery, whereas those with extensive disease were more likely to be offered chemotherapy instead. In the absence of randomised controlled trials, the best evidence is obtained from case-matched studies. 
